Daniel Cassuto

Dr. Daniel Cassuto


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
OAOfir Artzi
Ofir Artzi
JCJoel L. Cohen
Joel L. Cohen
JDJeffrey S Dover
Jeffrey S Dover
ATCHIMA SUWANCHINDAATCHIMA SUWANCHINDA
ATCHIMA SUWANCHINDA
TPTatjana Pavicic
Tatjana Pavicic
DSDana Shalmon
Dana Shalmon
Background and Objectives: There is a wide diversity of opinions regarding the management of delayed inflammatory reactions (DIRs) secondary to hyaluronic acid (HA)-based fillers. The plethora of approaches has led the authors to conduct a review regarding management and treatment of DIRs as well as establish therapeutic guidelines for this purpose. Materials and Methods: A review of the literature was performed through databases such as PubMed using keywords including HA-fillers and complications, delayed HA filler sequelae and therapy, soft tissue and dermal filler reactions and management. Additionally, a survey comprised of questions regarding the management and treatment of DIRs was sent to 18 physicians highly experienced with soft-tissue filler injections in 10 countries. Their answers and recommendations were analyzed and debated amongst these panelists. Results: Sixteen panelists favored antibiotic therapy as first-line treatment for DIRs, specifically dual antibiotic therapy consisting of a fluoroquinolone along with a tetracycline or macrolide for a period of 3– 6 weeks. The majority refrained from the use of intralesional (IL) or systemic steroids except in the case of disfiguring or recalcitrant reactions. IL hyaluronidase was recommended by 13 panelists; however, some preferred a watchful waiting approach for a period of 48 hours to 2 weeks prior to IL hyaluronidase, and in cases where antibiotics did not lead to improvement. Conclusion: A consensus was reached and summarized to propose a clear, easy-to-follow, stepwise algorithm for the treatment of DIRs.

1 December 2021 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
DCDaniel Cassuto
Daniel Cassuto
GBGilberto Bellia
Gilberto Bellia
CSChiara Schiraldi
Chiara Schiraldi
Hyaluronic acid (HA)-based injectable filling agents are at the forefront of the current demand for noninvasive dermatological procedures for the correction of age-related soft tissue defects. The present review aims to summarize currently available HA-based products and critically appraise their differences in rheological nature and clinical application. Linear HA (LHA) gels may be supplemented with amino acids, lipoic acid, vitamins, nucleosides, or minerals for synergistic antiaging and antioxidant benefits (polycomponent LHA). HA hydrogels can be generated via chemical or physical crosslinking, which increases their elasticity and decreases viscosity. The performance of crosslinked fillers depends on HA concentration, degree of crosslinking, elastic modulus, cohesivity, and type of crosslinking agent employed. PEG-crosslinked LHA displays improved elasticity and resistance to degradation, and lower swelling rates as compared to BDDE-crosslinked LHA. Physical crosslinking stabilizes HA hydrogels without employing exogenous chemical compounds or altering hyaluronans’ natural molecular structure. Thermally stabilized hybrid cooperative HA complexes (HCC) are a formulation of high- and low-molecular-weight (H-HA and L-HA) hyaluronans, achieving high HA concentration, low viscosity with optimal tissue diffusion, and a duration comparable to weakly cross-linked gel. Our critical analysis evidences the importance of understanding different fillers’ properties to assist physicians in selecting the most appropriate filler for specific uses and for predictable and sustainable results.

19 January 2010 in Journal of Cosmetic and Laser Therapy
Verified
Journal Article
Closed access
PDF file
DCDaniel Cassuto
Daniel Cassuto
LSLuca Scrimali
Luca Scrimali
PSPaolo Siragò
Paolo Siragò
Background: Keloid scars continue to be a complex and poorly understood subject. The main problem faced by researchers is the lack of an animal model because keloids affect only humans. Traditional techniques for keloids and hypertrophic scars are still availble. More recently, lasers have gained an increasing role in the treatment of hypertrophic scars and keloids. Methods: A total of 37 consecutive patients (31 females and six males; F:M=5:1 ratio) with 48 scars (34 hypertrophic and 14 keloids) were included in this study. Patients ranged in age from 8 to 67 years (mean age 34 years) with Fitzpatrick skin types II–IV. The age of scars ranged from 3 to 35 months (average 9 months). The scars were classified according to the Vancouver Scars Scale (VSS). Clinical digital photography was performed under standard and cross-polarized illumination. Laser treatment was performed in association with silicone gel sheeting. Results: Overall, excellent resolution of the scars was achieved, with an initial average VSS score of 12.6 and a mean VSS final score of 3.3. Conclusion: The combined use of silicone gel sheeting and a 532-nm millisecond laser is an effective and safe treatment for hypertrophic scars and keloids.

1 January 2020 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
AGAnnalisa La Gatta
Annalisa La Gatta
chiara Schiraldichiara Schiraldi
chiara Schiraldi
GZGiovanna Zaccaria
Giovanna Zaccaria
DCDaniel Cassuto
Daniel Cassuto
Introduction: Hyaluronic Acid (HA) fillers are among the most used products in cosmetic medicine. Companies offer different formulations to allow full facial treatment and/or remodeling. Gels are being studied to establish the biophysical properties behind the specific clinical use and a correlation between the gel biophysical properties and their clinical performance. Clinicians’ awareness is growing about the potential benefit deriving from such biophysical characterization. Aim: The Aliaxin® line of HA dermal fillers is the object of this study. The study aimed to widen the biophysical characterization of these gels by investigating a variety of properties to better support their optimal use. Further, we aimed to provide some clinical findings to gain a deeper insight into the correlation between filler features and clinical outcome. Methods: The four gels of the line were investigated, for the first time, for their cohesivity and stability to Reactive Oxygen Species (ROS). Additional secondary rheological parameters; evidence of relative water-uptake ability; and some clinical findings on product safety, palpability and duration of the aesthetic effect are provided. Results and conclusion: The gels proved highly cohesive and sensitive to ROS action with stability declining with the decrease in the overall gel elasticity. The G* and complex viscosity values at clinically relevant frequencies and gel water-uptake ability are consistent with the relative clinical indication related to gel projection and hydration capacity. Clinical outcomes showed the safety of the products and a perception of palpability well correlating with the cohesive/viscosity properties of the gels. A similar duration of the aesthetic effect (up to 1 year) was observed despite the diverse in vitro gel stability. The results broaden our knowledge of these gels and may contribute to optimize their clinical use towards the improvement of patient safety and satisfaction. Initial clinical observation indicated that gel biophysical properties allow for a reliable prediction of gel palpability, while in vitro data on gel stability cannot be related to the duration of the observed skin improvement. The latter finding further corroborates the idea of a skin restoration process activated by the gels besides the physical volumetric action.

28 July 2023 in Gels
Verified
Journal Article
Open access
PDF file
DCDaniel Cassuto
Daniel Cassuto
CCClara Cigni
Clara Cigni
GBGilberto Bellia
Gilberto Bellia
CSChiara Schiraldi
Chiara Schiraldi
The aim of the case series was to determine the efficacy of a new medical device developed for adipose tissue restoration in the face. The medical device used the patented NAHYCO® Hybrid Technology to deliver 45 mg of high- (1400 ± 200 kDa) and 45 mg of low- (100 ± 20 kDa) molecular-weight hyaluronan, in 2 mL. Patients and methods: Twenty-two volunteers, aged 36–60 years. Two mL of Profhilo® Structura was injected using a 25 G cannula for each hemiface, into superficial fat compartment along the line from the preauricular area to the mandibular angle. Two injections were performed, and Profhilo Structura’s effect on restoring adipose tissue was evaluated immediately after treatment, and over a 6-month follow-up. The studied medical device revealed a pseudoplastic behavior and consistency that allowed easy extrusion from a syringe. It showed a lower viscosity compared to dermal fillers, based on crosslinked HA. Clinically, the soft tissue thickness increased immediately after injection, and the clinical improvement persisted across a 6-month follow-up. The self-reported satisfaction with the treatment showed an amelioration in the midface of all the subjects enrolled, with no adverse effects. Profhilo® Structura demonstrated a peculiar fat compartment integration, with a regenerating effect on adipose tissue senescence. The skin thickening and compaction effects were similar to those obtained using chemically crosslinked dermal fillers, while a natural look was preserved, and the use of crosslinking agents was avoided.

1 March 2022 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
GZGiovanna Zaccaria
Giovanna Zaccaria
DCDaniel Cassuto
Daniel Cassuto
ABAlessio Baccarani
Alessio Baccarani
ILIrene Laura Lusetti
Irene Laura Lusetti
GSGiorgio De Santis
Giorgio De Santis